ArticleThe pharmacogenomics journal2009
Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene.
Article in The pharmacogenomics journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis.Schizophrenia bulletin · 2016Pooled it
- Precision medicine to identify, prevent, and treat pediatric obesity.Pharmacotherapy · 2024Review
- Olanzapine use for the treatment of adolescents with anorexia nervosa - reflecting on research and clinical practice.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2024Article
- Novel Compounds in the Treatment of Schizophrenia-A Selective Review.Brain sciences · 2023Review
- Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.Behavioral sciences (Basel, Switzerland) · 2021Review
- Pharmacogenomics of Medication-Induced Weight Gain and Antiobesity Medications.Obesity (Silver Spring, Md.) · 2021Review
- Association of the HTR2C-759C/T polymorphism and antipsychotic-induced weight gain: a meta-analysis.General psychiatry · 2020Article
- Multi-Target Approach for Drug Discovery against Schizophrenia.International journal of molecular sciences · 2018Review
- Current Concepts and Treatments of Schizophrenia.Molecules (Basel, Switzerland) · 2018Review
- Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release.Diabetes, metabolic syndrome and obesity : targets and therapy · 2018Review
- Serotonergic Control of Metabolic Homeostasis.Frontiers in cellular neuroscience · 2017Review
- Serotonin Receptor 2C -759C/T Polymorphism and Weight Change or Treatment Response to Mirtazapine in Korean Depressive Patients.Psychiatry investigation · 2014Article
- 759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment.Clinical pharmacology & biopharmaceutics · 2013Article
- No Association between Serotonin Receptor 2C-759C/T Polymorphism and Weight Change or Treatment Response to Mirtazapine in Korean Depressive Patients.Psychiatry investigation · 2013Article
- Pharmacogenetics of antipsychotics: recent progress and methodological issues.Expert opinion on drug metabolism & toxicology · 2013Review
- Genetic variations in the serotoninergic system contribute to body-mass index in Chinese adolescents.PloS one · 2013Article
- Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.Molecular psychiatry · 2012Review
- Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study.The pharmacogenomics journal · 2012Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Weight gain, a serious problem associated with some antipsychotic drugs, notably olanzapine and clozapine, was suggested to be associated with -759C/T polymorphism of the 5-HT2C receptor gene. This study aimed to examine a potential association of two functional polymorphisms of the promoter region of this gene: -759C/T (rs3813929) and -697G/C (rs518147), with weight gain after 6 weeks of olanzapine monotherapy. It included 107 patients with schizophrenia; among them 36 are first-episode drug-naive patients. Analysis was carried out by PCR-restriction fragment length polymorphism. A protective effect of -759T and -697C alleles was found: significantly less patients with -697C (3/51) and no patient with -759T (0/28) alleles experienced body mass index increase >or=10% (P=0.0006 and 0.002, respectively). The same was true for drug-naive patients possessing any of the variant alleles. There was a significant association of haplotypes with a >or=10% body mass index increase (P=0.001). On the basis of the additional statistical analysis, the more important role of -697C allele was suggested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.